July 15th, 2026Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial CancerFirst-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.Read more